{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:10:26Z","timestamp":1792059026698,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceuticals","doi-asserted-by":"crossref","award":["."],"award-info":[{"award-number":["."]}],"id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03063-w","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T08:27:10Z","timestamp":1736324830000},"page":"1207-1221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Patrick","family":"Eugeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas P.","family":"Saikali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7168-8581","authenticated-orcid":false,"given":"Zhongzheng","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice T.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda J.","family":"Krasenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Seminerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer W.","family":"McVige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"1","key":"3063_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.","journal-title":"J Headache Pain"},{"key":"3063_CR2","doi-asserted-by":"crossref","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396(10258):1204\u201322.","DOI":"10.1016\/S0140-6736(20)30925-9"},{"issue":"3","key":"3063_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/head.14053","volume":"61","author":"AK Kawata","year":"2021","unstructured":"Kawata AK, Shah N, Poon JL, et al. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study. Headache. 2021;61(3):438\u201354.","journal-title":"Headache"},{"issue":"3","key":"3063_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia. 2019;39(3):445\u201358.","journal-title":"Cephalalgia"},{"key":"3063_CR5","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28:1716.","journal-title":"Eur J Neurol"},{"key":"3063_CR6","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95:e2487\u201399.","journal-title":"Neurology"},{"key":"3063_CR7","doi-asserted-by":"publisher","first-page":"251581632110204","DOI":"10.1177\/25158163211020419","volume":"4","author":"A Bogdanov","year":"2021","unstructured":"Bogdanov A, Chia V, Bensink M, et al. Early use of erenumab in US real-world practice. Cephalal Reports. 2021;4:251581632110204.","journal-title":"Cephalal Reports"},{"key":"3063_CR8","unstructured":"AJOVY AJOVY (fremanezumab-vfrm) [prescribing information]. North Wales (PA): Teva Pharmaceuticals USA, Inc. Revised 2020. https:\/\/www.ajovyhcp.com\/globalassets\/ajovy\/ajovy-pi.pdf. 2020."},{"issue":"1","key":"3063_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-021-01279-7","volume":"22","author":"M Ashina","year":"2021","unstructured":"Ashina M, Cohen JM, Galic M, et al. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain. 2021;22(1):68.","journal-title":"J Headache Pain"},{"issue":"1","key":"3063_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s10194-022-01411-1","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen MT, Cohen JM, Patterson-Lomba O, et al. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. J Headache Pain. 2022;23(1):47.","journal-title":"J Headache Pain"},{"key":"3063_CR11","doi-asserted-by":"crossref","unstructured":"Driessen MT, Cohen JM, Thompson SF, et al. Real-world effectiveness of fremanezumab treatment for patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain 2022; (Epublished ahead of print).","DOI":"10.1186\/s10194-022-01415-x"},{"key":"3063_CR12","unstructured":"Ashina M, Mitsikostas DD, Amin FM, et al. Effectiveness of fremanezumab for preventive treatment of migraine: the observational PEARL study. 2022: Oral presentation presented at: The 8th European Academy of Neurology (EAN) Congress; June 25\u201328, 2022; Vienna, Austria."},{"key":"3063_CR13","doi-asserted-by":"crossref","unstructured":"Straube A, Broessner G, Gaul C, et al. Fremanezumab for preventive treatment in migraine: the FINESSE Study (P16-2.001). Neurology. 2022;98(Supplement 18):1678.","DOI":"10.1212\/WNL.98.18_supplement.1678"},{"issue":"6","key":"3063_CR14","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/jcm11061656","volume":"11","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Villar-Martinez MD, Goadsby PJ. New generation gepants: migraine acute and preventive medications. J Clin Med. 2022;11(6):1656.","journal-title":"J Clin Med"},{"issue":"23","key":"3063_CR15","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230\u201341.","journal-title":"N Engl J Med"},{"issue":"10200","key":"3063_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737\u201345.","journal-title":"Lancet"},{"issue":"8","key":"3063_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1080\/03007995.2022.2091333","volume":"38","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Hoyt M, Ye W, Nicholson R. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication. Curr Med Res Opin. 2022;38(8):1451\u20137.","journal-title":"Curr Med Res Opin"},{"key":"3063_CR18","unstructured":"UBRELVY UBRELVY\u00ae (ubrogepant) tablets [prescribing information]. Madison: Allergan USA, Revised 2021. 2021."},{"key":"3063_CR19","unstructured":"Biohaven Pharmaceuticals NURTEC ODT (rimegepant) prescribing information. New Haven: Biohaven Pharmaceuticals, Inc. March 2020. 2020."},{"issue":"4","key":"3063_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/head.14095","volume":"61","author":"A Jakate","year":"2021","unstructured":"Jakate A, Blumenfeld AM, Boinpally R, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642\u201352.","journal-title":"Headache"},{"issue":"8","key":"3063_CR21","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, Croop R, Kudrow D, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60(8):1734\u201342.","journal-title":"Headache"},{"issue":"20","key":"3063_CR22","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","volume":"94","author":"K Mullin","year":"2020","unstructured":"Mullin K, Kudrow D, Croop R, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 2020;94(20):e2121\u20135.","journal-title":"Neurology"},{"issue":"2","key":"3063_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40120-024-00586-w","volume":"13","author":"T Alsaadi","year":"2024","unstructured":"Alsaadi T, Suliman R, Santos V, et al. Safety and tolerability of combining CGRP monoclonal antibodies with gepants in patients with migraine: a retrospective study. Neurol Ther. 2024;13(2):465\u201373.","journal-title":"Neurol Ther"},{"issue":"12","key":"3063_CR24","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/jnnp-2020-324674","volume":"92","author":"JC Ray","year":"2021","unstructured":"Ray JC, Kapoor M, Stark RJ, et al. Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects. J Neurol Neurosurg Psychiatry. 2021;92(12):1325\u201334.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3063_CR25","doi-asserted-by":"publisher","first-page":"1130239","DOI":"10.3389\/fpain.2023.1130239","volume":"4","author":"T Shah","year":"2023","unstructured":"Shah T, Bedrin K, Tinsley A. Calcitonin gene relating peptide inhibitors in combination for migraine treatment: a mini-review. Front Pain Res (Lausanne). 2023;4:1130239.","journal-title":"Front Pain Res (Lausanne)"},{"issue":"22","key":"3063_CR26","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322.","journal-title":"N Engl J Med"},{"issue":"10203","key":"3063_CR27","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030\u201340.","journal-title":"Lancet"},{"issue":"1","key":"3063_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-022-01413-z","volume":"23","author":"LJ Krasenbaum","year":"2022","unstructured":"Krasenbaum LJ, Pedarla VL, Thompson SF, et al. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. J Headache Pain. 2022;23(1):54.","journal-title":"J Headache Pain"},{"issue":"1","key":"3063_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s10194-021-01358-9","volume":"22","author":"P McAllister","year":"2021","unstructured":"McAllister P, Lamerato L, Krasenbaum LJ, et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021;22(1):156.","journal-title":"J Headache Pain"},{"issue":"S1","key":"3063_CR30","first-page":"83","volume":"62","author":"LJ Krasenbaum","year":"2022","unstructured":"Krasenbaum LJ, Driessen MT, Ramirez Campos V, et al. Reductions in acute medication use, migraine-related health care resource utilization, and costs for patients initiating fremanezumab: results of a long-term US claims database analysis [AHS abstract P-95]. Headache. 2022;62(S1):83\u20134.","journal-title":"Headache"},{"issue":"S1","key":"3063_CR31","first-page":"80","volume":"62","author":"DC Buce","year":"2022","unstructured":"Buce DC, Driessen MT, Krasenbaum LJ, et al. Real-world impact of fremanezumab on migraine-related health care utilization and costs in patients with common comorbidities, acute medication overuse, or difficult-to-treat migraine [AHS abstract P-91]. Headache. 2022;62(S1):80\u20131.","journal-title":"Headache"},{"key":"3063_CR32","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2147\/PPA.S182563","volume":"12","author":"JH Ford","year":"2018","unstructured":"Ford JH, Foster SA, Stauffer VL, et al. Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine. Patient Prefer Adher. 2018;12:2413\u201324.","journal-title":"Patient Prefer Adher"},{"issue":"1","key":"3063_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-021-01238-2","volume":"22","author":"SJ Tepper","year":"2021","unstructured":"Tepper SJ, Fang J, Vo P, et al. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study. J Headache Pain. 2021;22(1):27.","journal-title":"J Headache Pain"},{"issue":"1","key":"3063_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s10194-020-01185-4","volume":"21","author":"ML Sumelahti","year":"2020","unstructured":"Sumelahti ML, Sumanen M, Sumanen MS, et al. My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland. J Headache Pain. 2020;21(1):118.","journal-title":"J Headache Pain"},{"issue":"6","key":"3063_CR35","first-page":"645","volume":"28","author":"A Ambrosini","year":"2022","unstructured":"Ambrosini A, Estemalik E, Pascual J, et al. Changes in acute headache medication use and health care resource utilization: results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER). J Manag Care Spec Pharm. 2022;28(6):645\u201356.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"3063_CR36","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.pec.2021.08.006","volume":"105","author":"Q Wang","year":"2022","unstructured":"Wang Q, Adhikari SP, Wu Y, et al. Consultation length, process quality and diagnosis quality of primary care in rural China: a cross-sectional standardized patient study. Patient Educ Couns. 2022;105(4):902\u20138.","journal-title":"Patient Educ Couns"},{"issue":"9","key":"3063_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.18502\/kls.v4i9.3556","volume":"4","author":"E Fitri Surbakti","year":"2018","unstructured":"Fitri Surbakti E, Sari K. The relationship between consultation length and patient satisfaction: a systematic review. KnE Life Sci. 2018;4(9):41.","journal-title":"KnE Life Sci"},{"issue":"19","key":"3063_CR38","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999\u20132008.","journal-title":"JAMA"},{"issue":"1","key":"3063_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, et al. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 2022;23(1):46.","journal-title":"J Headache Pain"},{"issue":"5","key":"3063_CR40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.amj.2007.06.007","volume":"26","author":"EA Panacek","year":"2007","unstructured":"Panacek EA. Performing chart review studies. Air Med J. 2007;26(5):206\u201310.","journal-title":"Air Med J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03063-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03063-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03063-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:53:08Z","timestamp":1738407188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03063-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3063"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03063-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patrick Eugeni, Megan E. Rooney, Nicolas P. Saikali, Zhongzheng Niu, and Jennifer W. McVige are employees of the Dent Neurological Institute, which performed this study funded by Teva Pharmaceuticals. Jennifer W. McVige has received research funding from AbbVie, Teva Pharmaceuticals, Eli Lilly, Amgen, and Lundbeck; and speaking\/consulting fees from AbbVie, Teva Pharmaceuticals, Eli Lilly, Amgen, Lundbeck, Avanir, Theranica, and Amneal. Maurice T. Driessen and Lynda J. Krasenbaum are employees of Teva Pharmaceuticals. Karen Carr and Michael J. Seminerio are former employees of Teva Pharmaceuticals (current affiliation: AbbVie, North Chicago, IL, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As this was a retrospective database research using routine clinical practice data, a waiver of authorization for use and disclosure of protected health information (PHI) was granted by the WCG IRB on August 26, 2021. This study was in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}